Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2016 Standout
An engineered 4-1BBL fusion protein with “activity on demand”
2020
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
2019 Science
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
2023
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
2012
Hypoxic control of metastasis
2016 Science
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists
2024 StandoutScienceNobel
Endothelial Hypoxia-Inducible Factor-1α Is Required for Vascular Repair and Resolution of Inflammatory Lung Injury through Forkhead Box Protein M1
2019
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
Oxygen availability and metabolic reprogramming in cancer
2017
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Discoveries in structure and physiology of mechanically activated ion channels
2020 StandoutNatureNobel
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Mechanisms of hypoxia signalling: new implications for nephrology
2019 StandoutNobel
Modular and tunable biological feedback control using a de novo protein switch
2019 StandoutNatureNobel
Combining immunotherapy and targeted therapies in cancer treatment
2012
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
The SIN3A histone deacetylase complex is required for a complete transcriptional response to hypoxia
2017 StandoutNobel
Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity
2019 Nature
The biology and management of non-small cell lung cancer
2018 StandoutNature
Deciphering and Reversing Tumor Immune Suppression
2013
The Principles of Engineering Immune Cells to Treat Cancer
2017
Type I interferons in infectious disease
2015 Standout
Control of the Immune Response by Pro-Angiogenic Factors
2014
Regulation of immunity and inflammation by hypoxia in immunological niches
2017
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
2013
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
2018
Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
2010
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
2014
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)–mediated induction of the long noncoding RNA NICI
2019 StandoutNobel
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
2015
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab
2013
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
2018
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Combinations of Bevacizumab With Cancer Immunotherapy
2018
Immune checkpoint modulation: Rational design of combination strategies
2015
Genome-wide analysis revealsNRP1as a direct HIF1α-E2F7 target in the regulation of motorneuron guidancein vivo
2015
Emerging Biological Principles of Metastasis
2017 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment
2014
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Hypoxia: Signaling the Metastatic Cascade
2016
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Mitochondrial TCA cycle metabolites control physiology and disease
2020 Standout
Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
2014
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
2013
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
2018
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
2014
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
2015
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
2017
An immune-active tumor microenvironment favors clinical response to ipilimumab
2011
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
2013
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
2015
Nuclear entry and export of FIH are mediated by HIF1α and exportin1, respectively
2018 StandoutNobel
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Chimeric Antigen Receptor Therapy
2018 Standout
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Metabolic reprogramming and cancer progression
2020 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Endothelial Hypoxia-Inducible Factor-2α Is Required for the Maintenance of Airway Microvasculature
2019 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
2016
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
2015
Works of Asís Palazón being referenced
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
2013
Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes
2011
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
2017
S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate
2016 Nature
Immune Response Regulation in the Tumor Microenvironment by Hypoxia
2015
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
2009
Intratumoral injection of interferon‐α and systemic delivery of agonist anti‐CD137 monoclonal antibodies synergize for immunotherapy
2010
Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
2010
Effects of IFN‐α as a signal‐3 cytokine on human naïve and antigen‐experienced CD8+ T cells
2010
Constitutive Glycolytic Metabolism Supports CD8+ T Cell Effector Memory Differentiation during Viral Infection
2016
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
2010
The Factor Inhibiting HIF Asparaginyl Hydroxylase Regulates Oxidative Metabolism and Accelerates Metabolic Adaptation to Hypoxia
2018
Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN‐α
2010
In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb
2009
Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells
2010
HIF Transcription Factors, Inflammation, and Immunity
2014
T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes
2013
Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer
2011
Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
2008
The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
2012